| Ytd | -66.76% | |
| 1y | -50.13% |
| Open | 3.77 | Prev Close | 3.77 | Low | 3.75 | High | 3.81 | Mkt Cap | 286.88M |
| Vol | 3.66M | Avg Vol | 1.75M | EPS | -1.21 | P/E | N/A | Forward P/E | -3.84 |
| Beta | 2.23 | Short Ratio | 7.67 | Inst. Own | 89.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 3.75 | 200-d Avg | 7.03 | 1yr Est | 5.29 |
FULC News
New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP is investiga
Biogen (NASDAQ: BIIB - Get Free Report) and Fulcrum Therapeutics (NASDAQ: FULC - Get Free Report) ar
New York, New York--(Newsfile Corp. - September 16, 2026) - Kaplan Fox & Kilsheimer LLP is investiga
Are ARX, FULC, EFSI Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 15, 2026I
New York, New York--(Newsfile Corp. - September 14, 2026) - Kaplan Fox & Kilsheimer LLP is investiga
New York, New York--(Newsfile Corp. - September 10, 2026) - Kaplan Fox & Kilsheimer LLP is investiga
BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the follow
New York, New York--(Newsfile Corp. - September 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigat
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Fulcrum Therapeutics,
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge
New York, New York--(Newsfile Corp. - September 4, 2026) - Kaplan Fox & Kilsheimer LLP is investigat
New York, New York--(Newsfile Corp. - September 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigat
BlackRock Inc. bought a new position in Fulcrum Therapeutics, Inc. (NASDAQ: FULC) in the undefined q
New York, New York--(Newsfile Corp. - August 31, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
Are UTZ, VCTR, FULC, CZR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 28,
New York, New York--(Newsfile Corp. - August 28, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
New York, New York--(Newsfile Corp. - August 26, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi
New York, New York--(Newsfile Corp. - August 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, T
Fulcrum Therapeutics and Slate Medicines merge in an all-stock deal to develop migraine drugs, backe
Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-
On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restru
Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins
Analyst rating changes: Stifel and Piper Sandler downgrade FULC, while Truist, Jefferies downgrade T
Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and
Piper Sandler analyst Edward Tenthoff downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweig
Truist Securities analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to
Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outpe
Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, H
Wall Street analysts changed outlook on top names. Read about analyst rating downgrades on ED, FULC,
HC Wainwright & Co. analyst Andrew S. Fein downgrades Fulcrum Therapeutics (NASDAQ:FULC) from
HPE stock jumps 26.55% after reporting strong revenue growth. Top gainers are DXST, MRVL and more. T
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug
― Company to explore strategic alternatives to maximize stockholder value ―CAMBRIDGE, Mass., June 01
On May 28, 2026, Fulcrum received meeting minutes from recent end-of-phase interactions with the FDA
U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market.
MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information
Fulcrum's new sickle cell trial data show higher hemoglobin levels and no serious safety concern
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which met the anal
― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), re